3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Hyperphagia
3
Stomach Neoplasms
2
Pancreatic Neoplasms
1
Neutropenia
1
Mucositis
1
Malnutrition
1
Leukemia, Myeloid, Acute
1
Infections
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Colitis
1
Interventions
Voriconazole
4
Vancomycin
3
Fluconazole
3
Filgrastim
3
Ciprofloxacin
3
Caspofungin
3
liposomal amphotericin B
2
Trimethoprim, Sulfamethoxazole Drug Combination
2
Therapeutics
2
Piperacillin, Tazobactam Drug Combination
2
Peripheral Blood Stem Cell Transplantation
2
Melphalan
2
Itraconazole
2
Granulocyte Colony-Stimulating Factor
2
Fosfomycin
2
Daptomycin
2
Cyclophosphamide
2
Cefazolin
2
Antibiotic Prophylaxis
2
ziprasidone
1
threonic acid
1
telavancin
1
soybean oil, phospholipid emulsion
1
plerixafor
1
monalizumab
1
lime
1
human papillomavirus vaccine, L1 type 16, 18
1
fluorescein isothiocyanate-keyhole limpet hemocyanin
1
fludarabine phosphate
1
fish oil triglycerides
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Infections
×
fish oil triglycerides
×
Clear all
NCT00533078
2015-07-23
LUNCH1
Insel Gruppe AG, University Hospital Bern
Phase 2
Completed
14 enrolled